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Abstract
Angiogenesis is important in the pathogenesis of systemic
inflammatory rheumatic diseases, a family of related disorders that
includes rheumatoid arthritis and systemic sclerosis. Rheumatoid
arthritis is the rheumatic disease in which the role of angiogenesis
has been studied most extensively. However, whereas rheumatoid
arthritis is characterized by excessive angiogenesis, the situation is
not as clear cut in other rheumatic diseases. For example, systemic
sclerosis is characterized by reduced capillary density with
insufficient angiogenic responses. Results with angiogenesis
inhibitors are controversial, and there is - in parallel - a wide range
of upregulated angiogenic factors such as vascular endothelial
growth factor. Dysregulation of angiogenesis in systemic sclerosis
is accompanied by other pathogenic processes, including fibrosis,
autoimmunity and vasculopathy. Animal models with at least partial
features of the vasculopathy observed in systemic sclerosis include
wound healing models, graft versus host disease models and, in
particular, the University of California at Davis line 200 chicken
model of systemic sclerosis.
Introduction
Angiogenesis, the process of new blood vessel formation, is
controlled by a subtle balance between endogenous
stimulators, which induce blood vessel growth, and inhibitors,
which prevent growth. In processes such as wound healing,
angiogenesis is a well programmed cascade of events that
comprises a number of distinct steps. Angiogenic stimuli
activate endothelial cells, which produce proteolytic enzymes
that degrade the basement membrane and the perivascular
extracellular matrix. Endothelial cells proliferate and migrate
into the perivascular area, forming ‘primary sprouts’.
Subsequent lumenation of these primary sprouts leads to
formation of capillary loops, which is followed by synthesis of
a new basement membrane and blood vessel maturation to
complete tube-like structures through which blood can flow
[1] (Figure 1).
Like any biological system, inducers of angiogenesis are
counterbalanced by inhibitors. However, in angiogenesis the
inhibitors often outweigh the inducers, resulting in a normal
physiological balance. When the converse situation occurs,
conditions characterized by angiogenesis, such as inflam-
matory angiogenesis or angiogenesis related to tumour growth,
can develop. In this review we explore potential initiators of
vascular injury in two example inflammatory rheumatic
diseases, namely rheumatoid arthritis (RA) and scleroderma
(systemic sclerosis [SSc]), in which the angiogenic process
appears to be disrupted very differently. We also discuss
how the angiogenic process might be manipulated for thera-
peutic benefit in the treatment of these debilitating diseases.
Regulation and dysregulation of
angiogenesis in rheumatic diseases
The rheumatic diseases are a family of closely related
disorders that includes RA, SSc and systemic lupus erythema-
tosus. RA is characterized by excessive angiogenesis [2] and
it has been studied extensively in this regard.
Mediators of angiogenesis in rheumatoid arthritis
Proangiogenic mediators associated with RA include the
following (Table 1): growth factors such as vascular endo-
thelial growth factor (VEGF); cytokines such as tumour
necrosis factor (TNF)-α (which has many effects in addition
to angiogenesis); chemokines such as IL-8; and other
mediators, including endothelin (ET)-1.
VEGF, an endothelial selective mitogen that is secreted
predominantly by macrophages, is an important cytokine in
both angiogenesis and vasculogenesis [3]. There is evidence
suggesting that, in RA, VEGF expression is induced by
hypoxia. VEGF has a hypoxia-responsive element in its
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promoter region such that the hypoxic environment of the
inflamed RA joint activates the VEGF gene via binding of
hypoxia inducible factor. This in turn augments IL-1 or trans-
forming growth factor (TGF)-β induced synovial fibroblast
VEGF [4], which contributes significantly to angiogenesis in
the synovium and progression of RA.
The limited role played by VEGF in normal human physiology
makes it an attractive candidate for therapeutic intervention
[5]. Data from both human in vitro and animal in vivo studies
show that inhibition of VEGF attenuates arthritis. In one in
vitro study VEGF receptor-1 Fc suppressed RA synovial
endothelial cell proliferation [6], whereas in a mouse model of
collagen-induced arthritis anti-VEGF antibody reduced the
onset of angiogenesis as well as onset and severity of
arthritis [7,8]. In mouse collagen-induced arthritis, administra-
tion of antibodies against VEGF receptor-1 (Flt-1) or soluble
VEGF receptor 1 was shown to reduce synovial angiogenesis
and inflammatory arthritis [9-11]. By blocking angiogenesis
via inhibition of VEGF, it appears that it is possible to block
arthritis in these animal models.
Evidence of the importance of TNF-α as a proangiogenic
mediator in RA is illustrated by the effect of giving anti-TNF-α
to patients with RA. Administration of anti-TNF-α drugs to
patients with RA leads to vascular deactivation, including
decreased angiogenesis and endothelial cell markers [12].
Chemokines are also important in RA and SSc. Studies have
shown that the chemokine IL-8/CXC chemokine ligand
(CXCL)8 plays a role in the pathogenesis of RA synovitis.
This molecule is angiogenic and appears to be responsible
for much of the macrophage-derived angiogenic activity seen
in RA [13]. Interestingly, chemokines such as IL-8/CXCL8
that have an ELR motif (glutamic acid-leucine-arginine) are
angiogenic, whereas chemokines that lack this motif are
angiostatic [14]. Thus, structure clearly plays a role in
determining the angiogenic properties of chemokines and
thus their involvement in the pathophysiology of RA.
Role of endothelin in angiogenesis
Secreted by endothelial cells, ET-1 has a number of effects
on the vascular system, which include vasoconstriction, up-
regulation of VEGF, cell proliferation and vascular
remodelling. With respect to cell proliferation, ET-1 appears
not to act alone but rather works in conjunction with various
growth factors and cytokines. In combination with platelet-
derived growth factor, for example, ET-1 acts synergistically
to boost cell proliferation [15].
Figure 1
Key stages in the process of angiogenesis. This diagram summarizes the steps involved in the formation of new capillary blood vessels. Steps include
protease production, endothelial cell migration and proliferation, vascular tube formation, anastomosis of newly formed tubes, synthesis of a new
basement membrane and incorporation of pericytes. Reproduced with permission from Lowe et al. Br J Dermatol 1995 © Blackwell Publishing [1].Page 3 of 9
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In addition to its well recognized effects as a potent endoge-
nous vasoconstrictor and smooth muscle mitogen, ET-1 also
appears to have proangiogenic effects in some rheumatic
diseases. In patients with RA, levels of ET-1 in synovial fluid,
serum and plasma are elevated in comparison with those in
normal individuals [16-19]. Although this clearly does not
demonstrate a causal role for ET-1 in the pathophysiology of
RA, it may suggest some degree of involvement.
More robust evidence that ET-1 has proangiogenic effects is
derived from the results from several experimental studies,
including the rat corneal bioassay, in which its angiogenic
effect occurs independently of inflammation [20]. That study
compared the angiogenic effects in rat corneas of ET-1 and
two positive controls, namely murine VEGF and human IL-8/
CXCL8. Murine VEGF and human IL-8/CXCL8 were
associated with angiogenesis in 52% and 63% of corneas,
respectively, whereas ET-1 resulted in angiogenesis in 71%
of corneas. ET-1 has also been shown to be angiogenic in
the Matrigel plug model [21] and to stimulate human
umbilical vein endothelial cell migration and proliferation, an
effect that can be blocked by the action of an ET-1 receptor
subtype B antagonist [22]. In combination with VEGF, ET-1
stimulates capillary morphogenesis and activates the hypoxia
response pathway, which (as discussed above) leads to
VEGF expression [22,23] and angiogenesis in the synovium.
Additionally, ET-1 may trigger angiogenesis by stimulating the
production of nitric oxide and matrix metalloproteinase
(MMP)-2 [22,24].
Role of adhesion molecules in angiogenesis
As mentioned above, adhesion molecules play a pivotal role
in angiogenesis, often acting in concert with angiogenic
cytokines. Basic fibroblast growth factor, one of the first
angiogenic factors to be identified, and TNF-α increase levels
of  αvβ3 integrin, resulting in angiogenesis (Figure 2).
Conversely, MMP-2 is cleaved into a PEX fragment (a
noncatalytic MMP fragment with integrin-binding activity) that
acts as a negative regulator of angiogenesis [25]. In contrast,
the angiogenic growth factors VEGF and TGF-β can elevate
protein kinase C and act, in part, via αvβ5 integrin to mediate
angiogenesis. Given that cytokines appear to act via integrin
intermediaries in the angiogenic process, blocking integrins
potentially could be used to regulate angiogenesis. This has
in fact been demonstrated in several in vivo animal studies. In
a rabbit arthritis model, anti-αvβ3 was found to decrease
synovial angiogenesis and inflammation [26], whereas an oral
nonpeptide  αvβ3 antagonist was shown to ameliorate rat
adjuvant-induced arthritis both prophylactically and thera-
peutically [27]. In another study, a proapoptotic αvβ3 antagonist
composed of a RGD peptide linked to a heptapeptide dimer
was found to home selectively to arthritic endothelium in the
mouse collagen-induced arthritis model when compared with
normal joint and control organ endothelium [28]. The results of
this study have important implications for RA because they
suggest that it is possible to distinguish therapeutically
diseased endothelium from normal endothelium.
Despite this promising research, the role of adhesion
molecules as angiogenic mediators remains the subject of
much debate. The prevailing paradigm was that soluble
adhesion molecules are anti-inflammatory. It was believed that
adhesion molecules expressed on the wall of endothelial cells
could be cleaved so that they bind to leucocytes that would
normally bind to endothelial receptors on the endothelial wall
and then enter the tissue. In other words, these soluble
receptors were thought to act as blocking reagents, binding
to leucocytes and so preventing them from binding to their
respective receptors on endothelial cells and resulting in
inflammation.
An alternative paradigm, and one advocated here, is that
endothelial adhesion molecules are in fact shed and have
proinflammatory and proangiogenic effects. Evidence for this
alternative paradigm comes from experimental work on
soluble E-selectin and soluble vascular cell adhesion
molecule (VCAM)-1, which induced chemotaxis of human
endothelial cells in vitro and were angiogenic in rat corneas.
Soluble E-selectin acted on endothelial cells in part through a
sialylated Lewisx dependent mechanism [29], whereas
soluble VCAM-1 acted on endothelial cells in part through a
very late antigen-4 dependent mechanism. An antigen
structurally similar to sialylated Lewisx and designated 4A11
is also shed from endothelium and mediates angiogenesis
[30]. Using a monoclonal antibody (mAb 4A11) raised in
mice to adherent human RA synovial tissue cells, it has been
demonstrated that this novel endothelial selective antigen has
both proinflammatory and proangiogenic potential. In vitro
antibody binding experiments found massive upregulation of
4A11 antigen on the surface of TNF-α and thrombin-
Available online http://arthritis-research.com/content/9/S2/S3
Table 1
Some proangiogenic mediators involved in the pathogenesis
of rheumatoid arthritis
Type of molecule Molecule
Growth factors Fibroblast growth factor (FGF)-2
Transforming growth factor (TGF)-β
Hepatocyte growth factor (HGF)
Vascular endothelial growth factors (VEGF, 
VEGF-C, and VEGF-D)
Cytokines Tumour necrosis factor (TNF)-α
Platelet activating factor (PAF)
Angiopoietin (Ang)-1, Ang-2
Chemokines Interleukin (IL)-8
Epithelial neutrophil activating peptide 
(ENA)-78
Growth related gene product (GRO)-α
Stromal cell derived factor (SDF)-1
Fractalkine
Other mediators Endothelin (ET)-1stimulated endothelium compared with nonstimulated cells. In
contrast to soluble E-selectin and soluble VCAM-1, 4A11
antigen is rapidly cytokine induced in endothelial cells in vitro,
within 5 to 20 min, and declines within 2 hours of stimulation.
The effects observed in vitro have been confirmed in vivo in a
human poison ivy inflammatory model, in which 4A11 antigen
exhibited greater basal expression than either soluble E-
selectin or soluble VCAM-1, which are known cytokine
inducible, inflammatory antigens that are upregulated in this
model of contact dermatitis [31].
Increased expression of 4A11 antigen in RA synovial tissue
compared with normal synovial tissue and synovial fluid from
osteoarthritis patients, and a strong, positive angiogenic
response in a rat corneal bioassay provide further evidence
that this inducible endothelial selective antigen has
proinflammatory and angiogenic potential. Structural and
histological studies have shown that 4A11 consists of Lewisy
and H-2 glycoconjugate antigens (Ley/H). Except for a
presence on epithelial cells, such as keratinocytes, Ley/H
appear to be endothelium specific and, moreover, are
expressed selectively in synovium, lymphoid organs, and skin.
This suggests a role in organ-specific homing. It is believed
that in the milieu of the inflamed joint in RA, endothelial cells
become activated, perhaps by cytokines such as IL-1 and
TNF-α, to shed this Ley/H antigen. Subsequently, the Ley/H
antigen binds to an as yet unknown receptor that mediates
angiogenesis. Interestingly, mAb 4A11 was able to block the
strong angiogenic response induced by Ley and H analogues.
The balance of angiogenic factors in rheumatoid arthritis
In RA, the balance of angiogenic inducers and inhibitors
appears tipped in favour of inducers, leading to a state of
inflammatory angiogenesis. Endogenous inhibitors of angio-
genesis with relevance to rheumatic disease have none-
theless been identified. Of these, cartilage-derived factors
such as troponin I [32] and endostatin, a fragment of collagen
XVIII, appear important. In RA synovial tissue, endostatin can
decrease RA synovial tissue volume, inflammation and
angiogenesis when this tissue is implanted in a severe
combined immunodeficient mouse [33]. Transfer of the
endostatin lentiviral gene into TNF-α transgenic mice at the
onset of arthritis was found to reduce the arthritis index, a
measure of disease severity, as well as reducing the number of
synovial blood vessels [34]. To be effective therapeutically,
however, strategies to inhibit angiogenesis must block
abnormal but not normal blood vessel growth, such as occurs
during wound healing or the reproductive cycle. Indeed,
excessive vascular regression could compromise delivery of
therapeutic agents to the target site and cause unwanted side
effects. The use of anti-VEGF therapies in cancer patients,
although therapeutically effective, is not without side effects.
Hypertension and thromboembolism have occurred following
treatment with an anti-VEGF mAb or a small molecule drug that
targets VEGF receptor tyrosine kinase [35]. New approaches
to angiogenesis inhibition in the therapeutic management of RA
must therefore be explored, either by blocking inducers or by
enhancing inhibitors. There is also a need for better surrogate
markers of angiogenesis and its inhibition.
Dysregulation of angiogenesis in systemic
sclerosis
Whereas RA is characteristically a disease of increased
angiogenesis, there is evidence for an insufficient angiogenic
response in SSc. The dysregulation of angiogenesis leads to
failure to replace damaged vessels, resulting in a reduction in
capillary density in patients with SSc [36]. Clinically, these
changes in the capillary network are evident on nail-fold
capillaroscopy and may manifest as ischaemic fingertip ulcers.
Studies in peripheral blood mononuclear cells support the
concept of decreased and inefficient angiogenesis in SSc.
Isolated peripheral blood mononuclear cells induce less
angiogenesis than do peripheral blood mononuclear cells
from healthy control individuals [37], whereas supernatants
from SSc peripheral blood mononuclear cells decreased
endothelial chemotaxis [38], and serum samples from
patients with SSc failed to enhance normal mononuclear
angiogenic capability [39]. Thus, in contrast to the marked
angiogenic response seen in peripheral blood monocytes
from normal individuals, those from SSc patients are
effectively inert, leading to a defective or dysregulated
angiogenic response. Comparisons of skin biopsies from
SSc patients with normal skin samples have shown the
former to have fewer blood vessels, providing further
evidence for decreased angiogenesis in SSc [40].
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Figure 2
Potential mechanism of action of some adhesion molecules and
cytokines involved in angiogenesis in RA. Basic fibroblast growth
factor (bFGF) and tumour necrosis factor (TNF)-α act via αvβ3 integrin.
In contrast, vascular endothelial growth factor (VEGF) and
transforming growth factor (TGF)-β appear to act via increasing protein
kinase C (PKC) with subsequent action on αvβ5 integrin. Matrix
metalloproteinase (MMP)-2 is proteolytically cleaved into a PEX
fragment (a noncatalytic MMP fragment with integrin-binding activity)
that acts as a negative regulator of angiogenesis. RA, rheumatoid
arthritis. Adapted with permission from Koch. Arthritis Rheum 1998 
© John Wiley & Sons/American College of Rheumatology [71].Although an overall decrease in the angiogenic response is
well documented, the mechanisms that lead to the disturbed
angiogenesis are much less clear. Several antiangiogenic or
angiostatic mediators have been reported to be upregulated
in SSc, including endostatin, platelet factor 4, thrombo-
spondin, and IL-4 [41-44] (Table 2). However, results on
angiostatic factors in SSc are conflicting [42,45] or flawed by
low patient numbers or poor clinical characterization, and
heterogeneity of the study population. In addition, the
functional contribution of angiostatic factors to the disturbed
angiogenesis in SSc has not been addressed.
Evidence for a mechanism of dysregulated angiogenesis in
SSc has emerged from two recent experimental studies. The
first of these showed decreased urokinase plasminogen
activator dependent invasion, proliferation, and capillary
morphogenesis, and increased MMP-12 in SSc endothelial
cells [46]. In this study the authors were able to restore the
defect in the endothelium with an anti-MMP-12 antibody.
They also discovered that urokinase plasminogen activator
undergoes truncation between domains 1 and 2, thus
impairing its function. The second experimental study showed
evidence for decreased expression of tissue kallikreins 9, 11
and 12 in endothelial cells isolated from patients with SSc in
comparison with normal endothelial cells [47]. There is also
evidence that circulating endothelial cells are increased in
SSc as a marker of endothelial cell activation in comparison
with normal controls, and that this increase correlates with
disease activity scores [48]. Recent studies indicated that, in
addition to angiogenesis, the formation of new vessels from
precursor cells (vasculogenesis) is impaired in SSc [49].
However, findings regarding the role of vasculogenesis in
SSc are inconsistent [50], and this must be addressed by
further studies.
Paradoxically, there is upregulation or increased expression of
a large number of proangiogenic mediators despite the
defective angiogenesis in SSc. In addition, the bushy and
tortuous capillaries seen on nail-fold capillaroscopy could be
interpreted as futile attempts to build new vessels after
stimulation with angiogenic factors. Examples of upregulated
proangiogenic factors in SSc include soluble VCAM-1 in
peripheral blood monocytes, intercellular adhesion molecule-1
in peripheral blood monocytes and skin fibroblasts, E-selectin
and P-selectin in skin, ET-1 in monocytes and skin fibroblasts,
and monocyte chemoattractant molecule-1/CC chemokine
ligand 2 in different cell types in the skin [51-53] (Table 2).
Some adhesion molecules such as VCAM-1 and P-selectin,
as well as cytokines such as TNF-α and IL-8/CXCL8, have
more commonly been found in skin biopsies taken from
patients with SSc of duration 1 year or less, whereas other
molecules, for example IL-6, are upregulated in late stage
disease [54]. Taken together, these findings suggest that
certain cellular adhesion molecules and cytokines may play
differential roles in the early, inflammatory and later fibrotic
stages of SSc.
As an additional example, the potent angiogenic factor VEGF
is markedly over-expressed in various cell types in the skin of
SSc patients [55,56]. In parallel, VEGF receptors are
upregulated on endothelial cells in SSc. In agreement with
this finding, a number of studies confirmed that serum levels
of VEGF are significantly increased in SSc patients through-
out different disease stages [42,57-59]. The serum levels of
VEGF correlate significantly with the development of fingertip
ulcers. SSc patients with fingertip ulcers have increased
serum levels of VEGF as compared with healthy individuals,
but they are lower than in SSc patients without fingertip
ulcers [42]. These data indicate that there might be a
functional deficit of VEGF in SSc patients, which can be
overcome if the levels of VEGF exceed an individual threshold.
The mechanisms that lead to increased expression of VEGF
in SSc are unclear. In contrast to the situation in RA, hypoxia
induced expression of hypoxia inducible factor-1α does not
appear to play a major role in the induction of VEGF in SSc
[55], whereas induction by cytokines such as platelet-derived
growth factor and TGF-β appear to be more important.
A crucial point in the interpretation of the upregulation of
angiogenic factors in this disease is that angiogenic factors
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Table 2
Some antiangiogenic and proangiogenic mediators in systemic
sclerosis
Type of mediator Molecule
Antiangiogenic Endostatin (normal in some studies)
Platelet factor (PF)4
Thrombospondin
Interleukin (IL)-4
Proangiogenic Soluble vascular cell adhesion molecule 
(sVCAM)-1
Soluble E-selectin (sE-selectin; normal in 
some studies)
E-selectin
Soluble P-selectin (sP-selectin)
P-selectin
Soluble intercellular adhesion molecule 
(sICAM)-1/ICAM-1
CD44
Vascular endothelial growth factor (VEGF)
Vascular endothelial growth factor receptors 
(VEGFRs; VEGFR1 and VEGFR2)
IL-8
Monocyte chemoattractant protein 
(MCP)-1/CC chemokine ligand (CCL)2 
and CCR2 (receptor for MCP-1)
Macrophage inflammatory protein 
(MIP)-1α/CCL3
Fractalkine/CX3 chemokine ligand (CX3CL)1 
and CX3 chemokine receptor (CX3CR)1 
(receptor for fractalkine)
β-Thromboglobulin
Tumour necrosis factor (TNF)-α
Endothelin (ET)-1must be expressed in a strictly controlled temporal and
spatial distribution if they are to lead to the development of
functionally adequate new vessels. For instance, although the
upregulation of VEGF and other angiogenic factors might be
a compensatory mechanism for the initial effect of
unidentified angiostatic factors, the temporal kinetics of its
expression appear to be critical in overcoming the inhibitory
effects of angiostatic factors. In this regard, it has been
shown that a brief upregulation of VEGF results in instability
of newly formed vessels [60]. On the other hand, prolonged
over-expression of VEGF, as is seen in SSc patients through-
out various disease stages, also has deleterious effects
because the vessels fuse in an uncontrolled manner and form
a chaotic vessel network that is strikingly similar to the
disturbed capillary network observed in SSc [60]. In addition,
isolated microvascular endothelial cells from patients exhibit
an impaired response to VEGF in the Matrigel capillary
morphogenesis assay [46], indicating that VEGF receptor
signalling might be impaired in endothelial cells of SSc
patients. In contrast, functionally important gene poly-
morphisms that lead to an impairment in biological properties
of VEGF do not exist in SSc patients [61].
The individual functional consequences of the upregulated
angiogenic factors for defective angiogenesis in SSc has not
yet been addressed in detail. In this regard, it is important to
highlight the results of a randomized placebo controlled trial
conducted to evaluate the effects of the dual endothelin
receptor antagonist bosentan on wound healing of fingertip
ulcers in patients with SSc (RAPIDS-2 [RAndomized, double-
blind, Placebo-controlled, multi-center study to assess the effect
of bosentan on healing and prevention of Ischemic Digital ulcers
in patients with systemic Sclerosis-2]) [62]. Wound healing
requires angiogenesis, and ET-1 is among the group of
angiogenic factors that are upregulated in SSc (Table 2).
Interestingly, inhibition of ET-1 did not affect wound healing in
this clinical trial, indicating that ET-1 is of little functional
importance for the angiogenic responses in patients with SSc.
Models for the vasculopathy that is
characteristic of systemic sclerosis
Wound healing as a model for systemic sclerosis
Functional and structural vasculopathy, which manifests as
endothelial cell injury, is an early pathological feature of SSc.
This is followed, or paralleled, by immunological activation,
perivascular inflammation and fibrosis. As a model of matrix
alteration and tissue remodelling in SSc, the process of
wound healing provides valuable insights. In this context,
wound healing, at least in skin, is characterized by two
important features: inflammation followed by extracellular
matrix synthesis. During wound healing the early inflammatory
phase is followed by a proliferative phase and then a tissue
remodelling phase, in which TGF-β plays an important role in
myofibroblast maturation. The final phase of wound healing is
collagen formation. It has been suggested that innate
immunity, the body’s first line of defence against microbes
and mediated via Toll-like receptors (TLRs), is important in
wound healing. Myeloid differentiation primary response gene
88 (MyD88), which is one of several molecules that are
critical for signalling by most TLRs, provides a convenient tool
for determining the importance of TLRs in wound healing and
whether the inflammatory response that occurs during wound
healing leads to the production of TGF-β and ET-1. Ongoing
experimental studies in mechanically injured MyD88 knockout
mice, which is a useful model for examining the role of innate
immunity in wound healing and tissue remodelling, are
examining the rate of wound closure and degree of
inflammation compared with those in control mice. The role of
TLR signalling in SSc, however, remains to be determined.
Graft versus host disease as a model for systemic sclerosis
Graft versus host disease is another model from which to
gain insight into SSc vasculopathy because it mimics all three
elements of SSc, with effects on fibrosis, autoimmunity and
vascular disease. Murine chronic graft versus host disease
models can, for instance, be created by injecting cells from
B10.D2 mice into irradiated Balb/C or Balb/C rag2-/- mice, in
which there are only minor histocompatibility differences.
Within 4 to 6 weeks, this produces a scleroderma-like disease,
the characteristic features of which include fibrosis/matrix
deposition, a marked increase in myofibroblasts, autoantibody
production and dermal infiltration of immune cells, as well as
marked upregulation of ET-1 in skin and kidney tissue. It is
still unclear by which molecular factors the increase in
myofibroblasts is driven. Candidate molecules include TGF-β
and ET-1, but conceivably some of these characteristics are due
to effects from multiple factors and interactions between them.
The University of California at Davis chicken lines 200
and 206
The University of California at Davis (UCD) 200/206 chicken
model [63] is an important animal model for vascular changes
in SSc. Unlike some animal models, the UCD chicken lines
spontaneously develop an inherited scleroderma-like disease
exhibiting the entire spectrum of SSc, including vascular
occlusion, severe perivascular lymphocytic infiltration of the
skin and viscera, fibrosis of skin and internal organs, auto-
antibodies against nuclear antigens, anticardiolipin anti-
bodies, anti-endothelial cell antibodies (AECAs), rheumatoid
factors and distal polyarthritis [64-66].
Studies of skin lesions from UCD 200/206 chickens found
that AECA-dependent cellular cytotoxicity induced endo-
thelial cell apoptosis is a primary event in the pathogenesis of
the SSc-like disease in this animal model [67], potentially
mediated via the Fas pathway [68]. Similar findings of
endothelial cell apoptosis in early disease stages were
observed in skin biopsies from human SSc patients. These
findings subsequently received support from the observation
that AECA-positive serum from UCD 200 chickens injected
into normal chicken embryos results in AECA binding to
microvascular endothelium in vivo and a significant increase
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endothelial cell apoptosis, mononuclear cell infiltration and
collagen deposition in the visceral organs of UCD chickens
[70]. In this study, apoptotic endothelial cells were found in
oesophagus, lung and kidney of UCD 200 chickens at the
initial stage of the disease but not in heart or liver. In this
study oesophagus was the most affected organ, exhibiting
mononuclear cell infiltrations and increased collagen
deposition. This supports the hypothesis that endothelial cell
apoptosis initiates the disease process, followed by mono-
nuclear cell infiltration and fibrosis.
Conclusion
As this review illustrates, dysregulation of angiogenesis is an
important process in the pathogenesis of various rheumatic
diseases, including RA and SSc. In RA angiogenesis is
central to the formation of the inflammatory pannus and
permits leucocyte infiltration into the synovial tissue. More-
over, the extremely hypoxic environment of the arthritic
synovium acts as a potent signal for the generation of new
blood vessels. In contrast to RA, SSc is characterized by
decreased capillary density and insufficient angiogenesis.
However, despite the reduction in capillary density in the skin
of SSc patients, a number of proangiogenic factors are over-
expressed. Therapeutic manipulation of angiogenesis in
rheumatic diseases will depend on the net balance of
angiogenic and angiostatic events. In RA, in which inducers
of angiogenesis outweigh inhibitors, it is clear that blocking
angiogenesis blocks arthritis, thereby helping to ameliorate
the disease. The picture is less clear for SSc, and functional
experiments targeting angiogenic or angiostatic factors are
lacking. There are controversial data on upregulation of
angiostatic factors, which might serve as targets for
therapeutic approaches. In addition, the uncontrolled and
chronic expression of angiogenic factors such as VEGF
might have deleterious effects on the formation of new
vessels per se. The issues that must be addressed in SSc
therefore are whether it would be therapeutically useful to
augment angiogenesis and whether it is possible to
manipulate selectively the positive and negative effects of
mediators such as VEGF.
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